Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line

Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line

Abstract Background The aminoisoquinoline FX-9 shows pro-apoptotic and antimitotic effects against lymphoblastic leukemia cells and prostate adenocarcinoma cells. In contrast, decreased cytotoxic effects against non-neoplastic blood cells, chondrocytes, and fibroblasts were observed. However, the ac...

Full description

Bibliographic Details
Main Authors: F. Weiner, J. T. Schille, D. Koczan, X.-F. Wu, M. Beller, C. Junghanss, M. Hewicker-Trautwein, H. Murua Escobar, I. Nolte
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Cancer
Subjects:
Isoquinolinamine FX-9
Antimitotic agent
Microarray analysis
NF-κB signaling
G1-phase arrest
Prostate cancer
Online Access:https://doi.org/10.1186/s12885-021-08836-y

Internet

https://doi.org/10.1186/s12885-021-08836-y

Similar Items